Table 1 Real-world endpoints.

From: Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer

Variable

Definition

rwRR

Proportion of patients with a best overall response (BOR), real-world complete response (rwCR) or real-world partial response (rwPR) at least 14 days after study treatment initiation, among the total number of treated patients receiving their index line. The observation time of response spans from the index date to the earliest of the start of the subsequent line of therapy (LOT), death, last confirmed EHR activity date, or end of data

rwOS

Time in monthsᵃ from the start of the index line until death. Patients who did not have a recorded death event were censored at their last confirmed EHR activity date

rwPFS

Time in monthsᵃ from the start of the index line until the occurrence of real-world progression or death, at least 14 days after study treatment initiation. Patients who did not have a recorded progression or death event were censored at their last confirmed EHR activity date

rwTTNT

The time in monthsᵃ from the start of the index line until the switch to a new LOT or death. Patients who did not have a recorded next treatment event were censored at their last confirmed EHR activity date

rwTTD

The time in monthsᵃ from the start of the index line until discontinuation of treatment or death. Patients who did not have a recorded discontinuation event were censored at their last known index treatment use before data cut off

  1. BOR best overall response, EHR electronic health record, LOT lines of therapy, rwCR real-world complete response, rwOS real-world overall survival, rwPFS real-world progression-free survival, rwPR real-world partial response, rwRR real-world response rate, rwTTD real-world time to discontinuation, rwTTNT real-world time to next treatment.
  2. a1 month = 30.4375 days.
Back to article page